Nerviano partners with Genentech to develop anticancer drugs

NEW YORK A company that develops cancer drugs has announced a multi-year collaboration with Genentech.

Nerviano Medical Sciences said that it would collaborate with South San Francisco, Calif.-based Genentech to search for antibody drug compounds to develop anticancer drugs. It is the second agreement between Genentech and NMS in less than a year, NMS said.

Genentech will have exclusive rights to fully develop and commercialize licensed products, while NMS will primarily synthesize and manufacture drug reagents.